Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells


The purpose of this study is to evaluate the effects of Sarpogrelate in endothelial progenitor cells of patients with atherosclerosis.

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2012

Detailed Description

Endothelial progenitor cells play an important role in vasculogenesis and vascular repair. Sarpogrelate, a inhibitor of HT2A, is used an an anti-platelet drug, however, a direct effect in vascular cells is supposed.


  • Drug: Sarpogrelate
    • Sarpogrelate 300mg/day

Clinical Trial Outcome Measures

Primary Measures

  • The number and function of endothelial progenitor cells
    • Time Frame: 3 months

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with atherosclerosis

Exclusion Criteria

  • Patients with high risk of bleeding
  • Patients with pregnancy
  • Patients with allergic reaction of Salpogrelate

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Aichi Gakuin University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Keiko Naruse, Associate professor – Aichi Gakuin University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.